Physiologically Based Pharmacokinetic/Toxicokinetic Modeling

  • Jerry L. CampbellJr.
  • Rebecca A. Clewell
  • P. Robinan Gentry
  • Melvin E. Andersen
  • Harvey J. ClewellIII
Part of the Methods in Molecular Biology book series (MIMB, volume 929)


Physiologically based pharmacokinetic (PBPK) models differ from conventional compartmental pharmacokinetic models in that they are based to a large extent on the actual physiology of the organism. The application of pharmacokinetics to toxicology or risk assessment requires that the toxic effects in a particular tissue are related in some way to the concentration time course of an active form of the substance in that tissue. The motivation for applying pharmacokinetics is the expectation that the observed effects of a chemical will be more simply and directly related to a measure of target tissue exposure than to a measure of administered dose. The goal of this work is to provide the reader with an understanding of PBPK modeling and its utility as well as the procedures used in the development and implementation of a model to chemical safety assessment using the styrene PBPK model as an example.

Key words

PBPK Styrene Pharmacokinetics 


  1. 1.
    Andersen ME (1981) Saturable metabolism and its relation to toxicity. Crit Rev Toxicol 9:105–150PubMedCrossRefGoogle Scholar
  2. 2.
    Monro A (1992) What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? Toxicol Appl Pharmacol 112:171–181PubMedCrossRefGoogle Scholar
  3. 3.
    Andersen ME, Clewell HJ, Krishnan K (1995) Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Risk Anal 15:533–537PubMedCrossRefGoogle Scholar
  4. 4.
    Teorell T (1937) Kinetics of distribution of substances administered to the body. I. The extravascular mode of administration. Arch Int Pharmacodyn 57:205–225Google Scholar
  5. 5.
    Teorell T (1937) Kinetics of distribution of substances administered to the body. I. The intravascular mode of administration. Arch Int Pharmacodyn 57:226–240Google Scholar
  6. 6.
    O’Flaherty EJ (1987) Modeling: an introduction. National Research Council. In: Pharmacokinetics in risk assessment. Drinking water and health, vol 8. National Academy Press, Washington DC, pp. 27–35Google Scholar
  7. 7.
    Clewell HJ, Andersen ME (1985) Risk assessment extrapolations and physiological modeling. Toxicol Ind Health 1(4):111–131PubMedGoogle Scholar
  8. 8.
    Andersen ME, Clewell HJ, Gargas ML, Smith FA, Reitz RH (1987) Physiologically based pharmacokinetics and the risk assessment for methylene chloride. Toxicol Appl Pharmacol 87:185–205PubMedCrossRefGoogle Scholar
  9. 9.
    Gerrity TR, Henry CJ (1990) Principles of route-to-route extrapolation for risk assessment. Elsevier, New YorkGoogle Scholar
  10. 10.
    Clewell HJ, Jarnot BM (1994) Incorporation of pharmacokinetics in non-carcinogenic risk assessment: Example with chloropentafluorobenzene. Risk Anal 14:265–276PubMedCrossRefGoogle Scholar
  11. 11.
    Clewell HJ (1995) Incorporating biological information in quantitative risk assessment: an example with methylene chloride. Toxicology 102:83–94PubMedCrossRefGoogle Scholar
  12. 12.
    Clewell HJ (1995) The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicol Lett 79:207–217PubMedCrossRefGoogle Scholar
  13. 13.
    Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME (1995) Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. Chemosphere 31:2561–2578PubMedCrossRefGoogle Scholar
  14. 14.
    Clewell HJ, Andersen ME (1996) Use of physiologically-based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111:315–329PubMedCrossRefGoogle Scholar
  15. 15.
    Clewell HJ III, Gentry PR, Gearhart JM (1997) Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. J Toxicol Environ Health 52:475–515PubMedCrossRefGoogle Scholar
  16. 16.
    Himmelstein KJ, Lutz RJ (1979) A review of the application of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm 7:127–145PubMedGoogle Scholar
  17. 17.
    Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103–1126PubMedCrossRefGoogle Scholar
  18. 18.
    Fiserova-Bergerova V (1983) Modeling of inhalation exposure to vapors: uptake distribution and elimination, vol 1 and 2. CRC, Boca RatonGoogle Scholar
  19. 19.
    Bischoff KB (1987) Physiologically based pharmacokinetic modeling. National Research Council. In: Pharmacokinetics in Risk Assessment. Drinking water and health, vol 8. National Academy Press, Washington, DC, pp. 36–61Google Scholar
  20. 20.
    Leung HW (1991) Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J Toxicol Environ Health 32:247–267PubMedCrossRefGoogle Scholar
  21. 21.
    Clewell HJ, Andersen ME (1986) A multiple dose-route physiological pharmacokinetic model for volatile chemicals using ACSL/PC. In: Cellier FD (ed) Languages for continuous system simulation. Society for Computer Simulation, San Diego, pp 95–101Google Scholar
  22. 22.
    Ramsey JC, Andersen ME (1984) A physiological model for the inhalation pharmacokinetics of inhaled styrene monomer in rats and humans. Toxicol Appl Pharmacol 73:159–175PubMedCrossRefGoogle Scholar
  23. 23.
    Adolph EF (1949) Quantitative relations in the physiological constitutions of mammals. Science 109:579–585PubMedCrossRefGoogle Scholar
  24. 24.
    Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435–461PubMedGoogle Scholar
  25. 25.
    Dedrick RL, Bischoff KB (1980) Species similarities in pharmacokinetics. Fed Proc 39:54–59PubMedGoogle Scholar
  26. 26.
    McDougal JN, Jepson GW, Clewell HJ, MacNaughton MG, Andersen ME (1986) A physiological pharmacokinetic model for dermal absorption of vapors in the rat. Toxicol Appl Pharmacol 85:286–294PubMedCrossRefGoogle Scholar
  27. 27.
    Paustenbach DJ, Clewell HJ, Gargas ML, Andersen ME (1988) A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. Toxicol Appl Pharmacol 96:191–211PubMedCrossRefGoogle Scholar
  28. 28.
    Vinegar A, Seckel CS, Pollard DL, Kinkead ER, Conolly RB, Andersen ME (1992) Polychlorotrifluoroethylene (PCTFE) oligomer pharmacokinetics in Fischer 344 rats: development of a physiologically based model. Fundam Appl Toxicol 18:504–514PubMedCrossRefGoogle Scholar
  29. 29.
    Clewell HJ, Andersen ME (1989) Improving toxicology testing protocols using computer simulations. Toxicol Lett 49:139–158PubMedCrossRefGoogle Scholar
  30. 30.
    Bischoff KB, Brown RG (1966) Drug distribution in mammals. Chem Eng Prog Symp 62(66):33–45Google Scholar
  31. 31.
    Astrand P, Rodahl K (1970) Textbook of work physiology. McGraw-Hill, New YorkGoogle Scholar
  32. 32.
    International Commission on Radiological Protection (ICRP) (1975) Report of the task group on reference man. ICRP Publication 23Google Scholar
  33. 33.
    Environmental Protection Agency (EPA) (1988) Reference physiological parameters in pharmacokinetic modeling. EPA/600/6-88/004. Office of Health and Environmental Assessment, Washington, DCGoogle Scholar
  34. 34.
    Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095PubMedCrossRefGoogle Scholar
  35. 35.
    Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407–484PubMedGoogle Scholar
  36. 36.
    Sato A, Nakajima T (1979) Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br J Ind Med 36:231–234PubMedGoogle Scholar
  37. 37.
    Sato A, Nakajima T (1979) A vial equilibration method to evaluate the drug metabolizing enzyme activity for volatile hydrocarbons. Toxicol Appl Pharmacol 47:41–46PubMedCrossRefGoogle Scholar
  38. 38.
    Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen ME (1989) Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 98:87–99PubMedCrossRefGoogle Scholar
  39. 39.
    Jepson GW, Hoover DK, Black RK, McCafferty JD, Mahle DA, Gearhart JM (1994) A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundam Appl Toxicol 22:519–524PubMedCrossRefGoogle Scholar
  40. 40.
    Clewell HJ (1993) Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. Toxicol Lett 68:101–117PubMedCrossRefGoogle Scholar
  41. 41.
    Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128–1133PubMedCrossRefGoogle Scholar
  42. 42.
    Farris FF, Dedrick RL, King FG (1988) Cisplatin pharmacokinetics: application of a physiological model. Toxicol Lett 43:117–137PubMedCrossRefGoogle Scholar
  43. 43.
    Edginton AN, Theil FP, Schmitt W, Willmann S (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143–1152PubMedCrossRefGoogle Scholar
  44. 44.
    Andersen ME, Clewell HJ III, Gargas ML, MacNaughton MG, Reitz RH, Nolan R, McKenna M (1991) Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol Appl Pharmacol 108:14–27PubMedCrossRefGoogle Scholar
  45. 45.
    Andersen ME, Clewell HJ, Mahle DA, Gearhart JM (1994) Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. Toxicol Appl Pharmacol 128:158–165PubMedCrossRefGoogle Scholar
  46. 46.
    Fisher J, Gargas M, Allen B, Andersen M (1991) Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. Toxicol Appl Pharmacol 109:183–195PubMedCrossRefGoogle Scholar
  47. 47.
    Fisher JW, Allen BC (1993) Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. Risk Anal 13:87–95PubMedCrossRefGoogle Scholar
  48. 48.
    Allen BC, Fisher J (1993) Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal 13:71–86PubMedCrossRefGoogle Scholar
  49. 49.
    Corley RA, Mendrala AL, Smith FA, Staats DA, Gargas ML, Conolly RB, Andersen ME, Reitz RH (1990) Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 103:512–527PubMedCrossRefGoogle Scholar
  50. 50.
    Reitz RH, Mendrala AL, Corley RA, Quast JF, Gargas ML, Andersen ME, Staats DA, Conolly RB (1990) Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. Toxicol Appl Pharmacol 105:443–459PubMedCrossRefGoogle Scholar
  51. 51.
    Johanson G (1986) Physiologically based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. Toxicol Lett 34:23–31PubMedCrossRefGoogle Scholar
  52. 52.
    Bungay PM, Dedrick RL, Matthews HB (1981) Enteric transport of chlordecone (Kepone) in the rat. J Pharmacokinet Biopharm 9:309–341PubMedGoogle Scholar
  53. 53.
    Tuey DB, Matthews HB (1980) Distribution and excretion of 2,2′,4,4′,5,5′-hexabromobiphenyl in rats and man: pharmacokinetic model predictions. Toxicol Appl Pharmacol 53:420–431PubMedCrossRefGoogle Scholar
  54. 54.
    Lutz RJ, Dedrick RL, Tuey D, Sipes IG, Anderson MW, Matthews HB (1984) Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. Drug Metab Dispos 12(5):527–535PubMedGoogle Scholar
  55. 55.
    King FG, Dedrick RL, Collins JM, Matthews HB, Birnbaum LS (1983) Physiological model for the pharmacokinetics of 2,3,7,8-tetrachlorodibenzofuran in several species. Toxicol Appl Pharmacol 67:390–400PubMedCrossRefGoogle Scholar
  56. 56.
    Leung HW, Ku RH, Paustenbach DJ, Andersen ME (1988) A physiologically based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. Toxicol Lett 42:15–28PubMedCrossRefGoogle Scholar
  57. 57.
    Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Norbert D, Greenlee WF (1993) Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal 13(1):25–36PubMedCrossRefGoogle Scholar
  58. 58.
    O’Flaherty EJ (1991) Physiologically based models for bone seeking elements. I. Rat skeletal and bone growth. Toxicol Appl Pharmacol 111:299–312PubMedCrossRefGoogle Scholar
  59. 59.
    O’Flaherty EJ (1991) Physiologically based models for bone seeking elements. II. Kinetics of lead disposition in rats. Toxicol Appl Pharmacol 111:313–331PubMedCrossRefGoogle Scholar
  60. 60.
    O’Flaherty EJ (1991) Physiologically based models for bone seeking elements. III. Human skeletal and bone growth. Toxicol Appl Pharmacol 111:332–341PubMedCrossRefGoogle Scholar
  61. 61.
    O’Flaherty EJ (1993) Physiologically based models for bone seeking elements. IV. Kinetics of lead disposition in humans. Toxicol Appl Pharmacol 118:16–29PubMedCrossRefGoogle Scholar
  62. 62.
    O’Flaherty EJ (1995) Physiologically based models for bone seeking elements. V. Lead absorption and disposition in childhood. Toxicol Appl Pharmacol 131:297–308PubMedCrossRefGoogle Scholar
  63. 63.
    Mann S, Droz PO, Vahter M (1996) A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. Toxicol Appl Pharmacol 137:8–22PubMedCrossRefGoogle Scholar
  64. 64.
    Mann S, Droz PO, Vahter M (1996) A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol Appl Pharmacol 140:471–486PubMedCrossRefGoogle Scholar
  65. 65.
    Farris FF, Dedrick RL, Allen PV, Smith JC (1993) Physiological model for the pharmacokinetics of methyl mercury in the growing rat. Toxicol Appl Pharmacol 119:74–90PubMedCrossRefGoogle Scholar
  66. 66.
    McMullin TS, Hanneman WH, Cranmer BK, Tessari JD, Andersen ME (2007) Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Toxicology 240:1–14PubMedCrossRefGoogle Scholar
  67. 67.
    Lin Z, Fisher JW, Ross MK, Filipov NM (2011) A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. Toxicol Appl Pharmacol 251:16–31PubMedCrossRefGoogle Scholar
  68. 68.
    Kirman CR, Hays SM, Kedderis GL, Gargas ML, Strother DE (2000) Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrile-induced brain tumors to assess cancer potency in the rat. Risk Anal 20:135–151PubMedCrossRefGoogle Scholar
  69. 69.
    Sweeney LM, Gargas ML, Strother DE, Kedderis GL (2003) Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol Sci 71:27–40PubMedCrossRefGoogle Scholar
  70. 70.
    Takano R, Murayama N, Horiuchi K, Kitajima M, Kumamoto M, Shono F, Yamazaki H (2010) Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 58:252–258PubMedCrossRefGoogle Scholar
  71. 71.
    Clewell RA, Merrill EA, Robinson PJ (2001) The use of physiologically based models to integrate diverse data sets and reduce uncertainty in the prediction of perchlorate and iodide kinetics across life stages and species. Toxicol Ind Health 17:210–222PubMedCrossRefGoogle Scholar
  72. 72.
    Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Mattie DR, Robinson PJ, Fisher JW, Gearhart JM (2003) Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. Toxicol Sci 73:235–255PubMedCrossRefGoogle Scholar
  73. 73.
    Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Fisher JW, Gearhart JM (2003) Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling. Toxicol Sci 74:416–436PubMedCrossRefGoogle Scholar
  74. 74.
    Merrill EA, Clewell RA, Gearhart JM, Robinson PJ, Sterner TR, Yu KO, Mattie DR, Fisher JW (2003) PBPK predictions of perchlorate distribution and its effect on thyroid uptake of radioiodide in the male rat. Toxicol Sci 73:256–269PubMedCrossRefGoogle Scholar
  75. 75.
    Merrill EA, Clewell RA, Robinson PJ, Jarabek AM, Gearhart JM, Sterner TR, Fisher JW (2005) PBPK model for radioactive iodide and perchlorate kinetics and perchlorate-induced inhibition of iodide uptake in humans. Toxicol Sci 83:25–43PubMedCrossRefGoogle Scholar
  76. 76.
    McLanahan ED, Andersen ME, Campbell JL, Fisher JW (2009) Competitive inhibition of thyroidal uptake of dietary iodide by perchlorate does not describe perturbations in rat serum total T4 and TSH. Environ Health Perspect 117:731–738PubMedCrossRefGoogle Scholar
  77. 77.
    Haddad S, Charest-Tardif G, Tardif R, Krishnan K (2000) Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol Appl Pharmacol 167:199–209PubMedCrossRefGoogle Scholar
  78. 78.
    Haddad S, Beliveau M, Tardif R, Krishnan K (2001) A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol Sci 63:125–131PubMedCrossRefGoogle Scholar
  79. 79.
    Dennison JE, Andersen ME, Yang RS (2003) Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal Toxicol 15:961–986PubMedGoogle Scholar
  80. 80.
    Dennison JE, Andersen ME, Clewell HJ, Yang RSH (2004) Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. Environ Sci Technol 38:5674–5681PubMedCrossRefGoogle Scholar
  81. 81.
    Campbell JL, Fisher JW (2007) A PBPK modeling assessment of the competitive metabolic interactions of JP-8 vapor with two constituents, m-xylene and ethylbenzene. Inhal Toxicol 19:265–273PubMedCrossRefGoogle Scholar
  82. 82.
    Rowland M, Balant L, Peck C (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 6:56–67CrossRefGoogle Scholar
  83. 83.
    Ramsey JC, Young JD (1978) Pharmacokinetics of inhaled styrene in rats and humans. Scand J Work Environ Health 4:84–91PubMedCrossRefGoogle Scholar
  84. 84.
    Ramsey JC, Young JD, Karbowski R, Chenoweth MB, Mc Carty LP, Braun WH (1980) Pharmacokinetics of inhaled styrene in human volunteers. Toxicol Appl Pharmacol 53:54–63PubMedCrossRefGoogle Scholar
  85. 85.
    Stewart RD, Dodd HC, Baretta ED, Schaffer AW (1968) Human exposure to styrene vapors. Arch Environ Health 16:656–662PubMedGoogle Scholar
  86. 86.
    Gearhart JM, Clewell HJ, Crump KS, Shipp AM, Silvers A (1995) Pharmacokinetic dose estimates of mercury in children and dose-response curves of performance tests in a large epidemiological study. Water Air Soil Pollut 80:49–58CrossRefGoogle Scholar
  87. 87.
    Gearhart JM, Jepson GW, Clewell HJ, Andersen ME, Conolly RB (1990) Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol Appl Pharmacol 106:295–310PubMedCrossRefGoogle Scholar
  88. 88.
    Gearhart JM, Jepson GW, Clewell HJ, Andersen ME, Connoly RB (1995) A physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. Environ Health Perspect 102(11):51–60CrossRefGoogle Scholar
  89. 89.
    Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, Andersen ME (1989) Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichlorethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 99:395–414PubMedCrossRefGoogle Scholar
  90. 90.
    Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, Andersen ME (1990) Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichlorethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 102:497–513PubMedCrossRefGoogle Scholar
  91. 91.
    Luecke RH, Wosilait WD, Pearce BA, Young JF (1994) A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49:90–103PubMedCrossRefGoogle Scholar
  92. 92.
    Andersen ME, Gargas ML, Clewell HJ, Severyn KM (1987) Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene by gas uptake methods. Toxicol Appl Pharmacol 89:149–157PubMedCrossRefGoogle Scholar
  93. 93.
    Mumtaz MM, Sipes IG, Clewell HJ, Yang RSH (1993) Risk assessment of chemical mixtures: biological and toxicologic issues. Fundam Appl Toxicol 21:258–269PubMedCrossRefGoogle Scholar
  94. 94.
    Barton HA, Creech JR, Godin CS, Randall GM, Seckel CS (1995) Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol Appl Pharmacol 130:237–247PubMedCrossRefGoogle Scholar
  95. 95.
    Clewell HJ, Lee T, Carpenter RL (1994) Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal 14:521–531PubMedCrossRefGoogle Scholar
  96. 96.
    Andersen ME, Gargas ML, Ramsey JC (1984) Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism and the time course of enzyme induction for inhaled styrene in rats based on arterial blood:inhaled air concentration ratios. Toxicol Appl Pharmacol 73:176–187PubMedCrossRefGoogle Scholar
  97. 97.
    Andersen ME, Clewell HJ, Frederick CB (1995) Applying simulation modeling to problems in toxicology and risk assessment—a short perspective. Toxicol Appl Pharmacol 133:181–187PubMedCrossRefGoogle Scholar
  98. 98.
    Vinegar A, Winsett DW, Andersen ME, Conolly RB (1990) Use of a physiologically based pharmacokinetic model and computer simulation for retrospective assessment of exposure to volatile toxicants. Inhal Toxicol 2:119–128CrossRefGoogle Scholar
  99. 99.
    Vinegar A, Jepson GW (1996) Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologically-based pharmacokinetic modeling. Risk Anal 16:571–579PubMedCrossRefGoogle Scholar
  100. 100.
    Clewell HJ, Andersen ME, Wills RJ, Latriano L (1997) A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:S77–S85PubMedCrossRefGoogle Scholar
  101. 101.
    Fiserova-Bergerova V (1975) Biological—mathematical modeling of chronic toxicity. AMRL-TR-75-5. Aerospace Medical Research Laboratory, Wright-Patterson Air Force BaseGoogle Scholar
  102. 102.
    Gargas ML, Andersen ME (1989) Determining kinetic constants of chlorinated ethane metabolism in the rat from rates of exhalation. Toxicol Appl Pharmacol 97:230–246CrossRefGoogle Scholar
  103. 103.
    Gargas ML, Andersen ME, Clewell HJ (1986) A physiologically-based simulation approach for determining metabolic constants from gas uptake data. Toxicol Appl Pharmacol 86:341–352PubMedCrossRefGoogle Scholar
  104. 104.
    Gargas ML, Clewell HJ, Andersen ME (1990) Gas uptake techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal Toxicol 2:295–319CrossRefGoogle Scholar
  105. 105.
    Reitz RH, Mendrala AL, Guengerich FP (1989) In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically-based pharmacokinetic models. Toxicol Appl Pharmacol 97:230–246PubMedCrossRefGoogle Scholar
  106. 106.
    Filser JG, Bolt HM (1979) Pharmacokinetics of halogenated ethylenes in rats. Arch Toxicol 42:123–136PubMedCrossRefGoogle Scholar
  107. 107.
    Andersen ME, Gargas ML, Jones RA, Jenkins LH Jr (1980) Determination of the kinetic constants of metabolism of inhaled toxicant in vivo based on gas uptake measurements. Toxicol Appl Pharmacol 54:100–116PubMedCrossRefGoogle Scholar
  108. 108.
    Gargas ML, Clewell HJ, Andersen ME (1986) Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. Toxicol Appl Pharmacol 82:211–223PubMedCrossRefGoogle Scholar
  109. 109.
    Watanabe P, Mc Gown G, Gehring P (1976) Fate of [14] vinyl chloride after single oral administration in rats. Toxicol Appl Pharmacol 36:339–352PubMedCrossRefGoogle Scholar
  110. 110.
    Gargas ML, Andersen ME (1982) Metabolism of inhaled brominated hydrocarbons: validation of gas uptake results by determination of a stable metabolite. Toxicol Appl Pharmacol 66:55–68PubMedCrossRefGoogle Scholar
  111. 111.
    Lam G, Chen M, Chiou WL (1981) Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. J Pharm Sci 71(4):454–456CrossRefGoogle Scholar
  112. 112.
    O’Flaherty EJ (1995) PBPK modeling for metals. Examples with lead, uranium, and chromium. Toxicol Lett 82–83:367–372PubMedCrossRefGoogle Scholar
  113. 113.
    Environmental Protection Agency (EPA) (1992) EPA request for comments on draft report of cross-species scaling factor for cancer risk assessment. Fed Reg 57:24152Google Scholar
  114. 114.
    Carson ER, Cobelli C, Finkelstein L (1983) The mathematical modeling of metabolic and endocrine systems model formulation, identification, and validation. Wiley, New YorkGoogle Scholar
  115. 115.
    Rescigno A, Beck JS (1987) The use and abuse of models. J Pharmacokinet Biopharm 15:327–340PubMedGoogle Scholar
  116. 116.
    Yates FE (1978) Good manners in good modeling: mathematical models and computer simulations of physiological systems. Am J Physiol 234:R159–R160PubMedGoogle Scholar
  117. 117.
    Clewell HJ (1995) The use of physiologically based pharmacokinetic modeling in risk assessment: a case study with methylene chloride. In: Olin S, Farland W, Park C, Rhomberg L, Scheuplein R, Starr T, Wilson J (eds) Low-dose extrapolation of cancer risks: issues and perspectives. ILSI, Washington, DCGoogle Scholar
  118. 118.
    Allen BC, Covington TR, Clewell HJ (1996) Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111:289–303PubMedCrossRefGoogle Scholar
  119. 119.
    Clewell HJ, Andersen ME (1994) Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. Toxicol Ind Health 10:1–24PubMedGoogle Scholar
  120. 120.
    D’Souza RW, Francis WR, Andersen ME (1988) Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. J Pharmacol Exp Ther 245:563–568PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jerry L. CampbellJr.
    • 1
  • Rebecca A. Clewell
    • 1
  • P. Robinan Gentry
    • 2
  • Melvin E. Andersen
    • 1
  • Harvey J. ClewellIII
    • 1
  1. 1.The Hamner Institutes for Health SciencesResearch Triangle ParkUSA
  2. 2.Environ International CorporationMonroeUSA

Personalised recommendations